Search Results - xingming+deng

1 Results Sort By:
Small Molecule for Treatment-Resistant Lung Cancer
Application Small molecule agonist for treating cancers involving KRAS mutations. Key Benefits Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC). Selective for mutant KRAS lung cancer cells over normal cells. Non-toxic to normal cells. Market Summary Lung cancer patients with KRAS mutation(s) have a poor prognosis due...
Published: 2/13/2025   |   Inventor(s): Xingming Deng
Keywords(s): Oncology Treatments, Small Molecule
Category(s): TechPub Algolia > Drug Discovery, TechPub Algolia > Therapeutics